CFT7455 is designed to be highly potent and selective against its intended targets, IKZF1/3. The Phase 1/2 trial is designed to primarily investigate safety, tolerability, and anti-tumor activity. Secondary and exploratory objectives are to characterize the pharmacokinetic and pharmacodynamic profile of CFT7455. The Phase 1 portion of the study explores CFT7455 as a single agent in patients with relapsed or refractory (RR) multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), as well as in RRMM given with dexamethasone. Following identification of a recommended dose(s) and schedule(s), the Phase 2 portion of the trial is expected to expand to the following four investigational arms: (1) in RRMM, single agent CFT7455; (2) in RRMM, CFT7455 combined with dexamethasone; (3) in peripheral T-cell lymphoma, single agent CFT7455; and (4) in mantle cell lymphoma, single agent CFT7455.
Click here for more information on the CFT7455 clinical trial.
CFT8634 targets BRD9 for the treatment of cancers that are dependent on BRD9, including synovial sarcoma and SMARCB1-null cancers. The Phase 1/2 trial will primarily investigate safety, tolerability and anti-tumor activity with secondary and exploratory objectives to characterize the pharmacokinetic and pharmacodynamic profile of CFT8634. The Phase 1 portion of the study will evaluate CFT8634 as an oral, single agent therapy for patients with synovial sarcoma and SMARCB1-null tumors to identify a recommended Phase 2 dose. Following identification of recommended dosage, the Phase 2 portion of the trial is expected to expand to the following investigational arms: one in synovial sarcoma, and one in SMARCB1-null tumors.
Click here for more information on the CFT8634 clinical trial.
C4 Therapeutics, Inc., is committed to bringing new, innovative therapies to patients by continuously researching novel ways to treat cancer and other diseases through targeted protein degradation, conducting rigorous clinical trials and obtaining marketing approval by the U.S. Food and Drug Administration (FDA) and other regulatory authorities. As we advance our investigational therapies through clinical development, our goal is to provide access to these therapies at the appropriate time and in the manner that is in the best interest of the patients.
An expanded access program (EAP) , sometimes called compassionate use, is a potential pathway for a patient with a life-threatening condition or serious disease to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
On our website, both physicians and patients may explore information about our investigational agents. Our EAP policy is described below.
Several factors, consistent with guidelines published by the FDA and other regulatory agencies, are essential when considering expanded access requests, namely:
The illness must be serious or life-threatening with no other satisfactory treatment options (such as approved products or open clinical trials).
There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks, based on available safety and efficacy information.
The ability to provide a therapy in a fair and equitable manner so that there is adequate manufacturing capacity to provide therapies across all ongoing clinical trials and expanded access programs.
Whether granting expanded access would potentially compromise the scientific validity of broader development programs or interfere with or delay current clinical trials or regulatory filings designed to make the therapy available to many more patients.
Given the early stage of our development program, we believe that participation in our clinical trial, which is carefully designed to determine the safety and efficacy of our investigational therapy, is the most appropriate way to access our investigational therapy until sufficient evidence is available that suggests the potential benefit outweighs the risk. Therefore, we are not currently making our investigational product available through an expanded access program. If you have additional questions, please speak with your physician or have your physician contact email@example.com. We anticipate acknowledging receipt of requests sent to this email within five business days.
In line with the 21st Century Cures Act, C4 Therapeutics, Inc., may revise this policy at any time. This website and policy will be updated with a hyperlink or other reference to the expanded access record on clinicaltrials.gov if such program becomes active.